By Sabela Ojea

AstraZeneca PLC said Tuesday that its Enhertu drug has been approved in the European Union for patients with HER2-positive metastatic breast cancer .

The pharmaceutical giant said that the results of the Destiny-Breast03 study showed that Enhertu reduced the risk of disease progression or death by 72% when compared with trastuzumab emtansine.

Enhertu is jointly developed and commercialized by Astrazeneca and Daiichi Sankyo Co., the company said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

July 19, 2022 02:27 ET (06:27 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Astrazeneca.